Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Immutep Ltd ( (AU:IMM) ).
Immutep Limited has requested and received a voluntary suspension of trading in its ordinary shares on the ASX, following an earlier trading halt, while it prepares an announcement on the interim futility analysis of its Phase III TACTI-004 (KEYNOTE-F91) trial of lead candidate eftilagimod alfa. The company said the suspension, which is expected to last until it releases the futility analysis outcome or until trading commences on 13 March 2026, is intended to prevent trading in an uninformed market and will be lifted once the trial update is disclosed.
The most recent analyst rating on (AU:IMM) stock is a Buy with a A$0.65 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
More about Immutep Ltd
Immutep Limited is a biotechnology company listed on the ASX that develops immunotherapy treatments, with its lead drug candidate eftilagimod alfa under evaluation in advanced clinical trials. The company operates in the biopharmaceutical sector with a focus on oncology and immune-oncology therapies targeting global markets.
Average Trading Volume: 3,479,318
Technical Sentiment Signal: Buy
Current Market Cap: A$582.1M
For detailed information about IMM stock, go to TipRanks’ Stock Analysis page.